Luo et al. [34] suggested that KMP inhibits tumor angiogenesis in human ovarian cancer by suppressing vascular endothelial growth factor (VEGF) expression through a hypoxia-inducible factor (HIF)-dependent (AKT/HIF) pathway in ovarian cancer cells. This evidence concerns the gene AKT1 and ovarian cancer.